Literature DB >> 33994320

Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease.

Ettaib El Marabti1, Omar Abdel-Wahab2.   

Abstract

RNA splicing is the enzymatic process by which non-protein coding sequences are removed from RNA to produce mature protein-coding mRNA. Splicing is thereby a major mediator of proteome diversity as well as a dynamic regulator of gene expression. Genetic alterations disrupting splicing of individual genes or altering the function of splicing factors contribute to a wide range of human genetic diseases as well as cancer. These observations have resulted in the development of therapies based on oligonucleotides that bind to RNA sequences and modulate splicing for therapeutic benefit. In parallel, small molecules that bind to splicing factors to alter their function or modify RNA processing of individual transcripts are being pursued for monogenic disorders as well as for cancer.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  RNA; antisense oligonucleotides; muscular dystrophy; myelodysplastic syndromes; spinal muscular atrophy; splicing

Mesh:

Substances:

Year:  2021        PMID: 33994320      PMCID: PMC8238868          DOI: 10.1016/j.molmed.2021.04.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   15.272


  167 in total

1.  Modulation of RNA splicing as a potential treatment for cancer.

Authors:  John A Bauman; Ryszard Kole
Journal:  Bioeng Bugs       Date:  2011-05-01

2.  Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.

Authors:  Zhihua Feng; Karen K Y Ling; Xin Zhao; Chunyi Zhou; Gary Karp; Ellen M Welch; Nikolai Naryshkin; Hasane Ratni; Karen S Chen; Friedrich Metzger; Sergey Paushkin; Marla Weetall; Chien-Ping Ko
Journal:  Hum Mol Genet       Date:  2016-01-11       Impact factor: 6.150

Review 3.  Pre-mRNA splicing defects and RNA binding protein involvement in Niemann Pick type C disease.

Authors:  Francesca Paron; Andrea Dardis; Emanuele Buratti
Journal:  J Biotechnol       Date:  2020-05-06       Impact factor: 3.307

4.  Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Authors:  Jia Yi Fong; Luca Pignata; Pierre-Alexis Goy; Kimihito Cojin Kawabata; Stanley Chun-Wei Lee; Cheryl M Koh; Daniele Musiani; Enrico Massignani; Andriana G Kotini; Alex Penson; Cheng Mun Wun; Yudao Shen; Megan Schwarz; Diana Hp Low; Alexander Rialdi; Michelle Ki; Heike Wollmann; Slim Mzoughi; Florence Gay; Christine Thompson; Timothy Hart; Olena Barbash; Genna M Luciani; Magdalena M Szewczyk; Bas J Wouters; Ruud Delwel; Eirini P Papapetrou; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Mark D Minden; Jian Jin; Ari Melnick; Tiziana Bonaldi; Omar Abdel-Wahab; Ernesto Guccione
Journal:  Cancer Cell       Date:  2019-08-12       Impact factor: 31.743

5.  The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.

Authors:  Liang Chen; Jia-Yu Chen; Yi-Jou Huang; Ying Gu; Jinsong Qiu; Hao Qian; Changwei Shao; Xuan Zhang; Jing Hu; Hairi Li; Shunmin He; Yu Zhou; Omar Abdel-Wahab; Dong-Er Zhang; Xiang-Dong Fu
Journal:  Mol Cell       Date:  2018-01-27       Impact factor: 17.970

6.  Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Michele Lloyd-Puryear
Journal:  Muscle Nerve       Date:  2013-05-29       Impact factor: 3.217

7.  Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease.

Authors:  Kirupa Sathasivam; Andreas Neueder; Theresa A Gipson; Christian Landles; Agnesska C Benjamin; Marie K Bondulich; Donna L Smith; Richard L M Faull; Raymund A C Roos; David Howland; Peter J Detloff; David E Housman; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

8.  A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.

Authors:  Stefan Sturm; Andreas Günther; Birgit Jaber; Paul Jordan; Nada Al Kotbi; Nikhat Parkar; Yumi Cleary; Nicolas Frances; Tobias Bergauer; Katja Heinig; Heidemarie Kletzl; Anne Marquet; Hasane Ratni; Agnès Poirier; Lutz Müller; Christian Czech; Omar Khwaja
Journal:  Br J Clin Pharmacol       Date:  2018-11-16       Impact factor: 4.335

9.  Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.

Authors:  Mariko Taniguchi-Ikeda; Kazuhiro Kobayashi; Motoi Kanagawa; Chih-chieh Yu; Kouhei Mori; Tetsuya Oda; Atsushi Kuga; Hiroki Kurahashi; Hasan O Akman; Salvatore DiMauro; Ryuji Kaji; Toshifumi Yokota; Shin'ichi Takeda; Tatsushi Toda
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

Review 10.  Eteplirsen in the treatment of Duchenne muscular dystrophy.

Authors:  Kenji Rowel Q Lim; Rika Maruyama; Toshifumi Yokota
Journal:  Drug Des Devel Ther       Date:  2017-02-28       Impact factor: 4.162

View more
  5 in total

1.  Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12.

Authors:  Zixiang Wang; Shourong Wang; Junchao Qin; Xiyu Zhang; Gang Lu; Hongbin Liu; Haiyang Guo; Ligang Wu; Victoria O Shender; Changshun Shao; Beihua Kong; Zhaojian Liu
Journal:  Nat Commun       Date:  2022-10-21       Impact factor: 17.694

Review 2.  Alternative RNA splicing in tumour heterogeneity, plasticity and therapy.

Authors:  Sebastian Öther-Gee Pohl; Kevin B Myant
Journal:  Dis Model Mech       Date:  2022-01-11       Impact factor: 5.758

Review 3.  Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.

Authors:  Jan Philipp Bewersdorf; Omar Abdel-Wahab
Journal:  Genes Dev       Date:  2022-03-01       Impact factor: 11.361

4.  Identification of the prognostic signature based on genomic instability-related alternative splicing in colorectal cancer and its regulatory network.

Authors:  Qiuying Ding; Zhengping Hou; Zhibo Zhao; Yao Chen; Lei Zhao; Yue Xiang
Journal:  Front Bioeng Biotechnol       Date:  2022-07-18

5.  High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance.

Authors:  Mariela Cortés-López; Laura Schulz; Mihaela Enculescu; Claudia Paret; Bea Spiekermann; Mathieu Quesnel-Vallières; Manuel Torres-Diz; Sebastian Unic; Anke Busch; Anna Orekhova; Monika Kuban; Mikhail Mesitov; Miriam M Mulorz; Rawan Shraim; Fridolin Kielisch; Jörg Faber; Yoseph Barash; Andrei Thomas-Tikhonenko; Kathi Zarnack; Stefan Legewie; Julian König
Journal:  Nat Commun       Date:  2022-09-22       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.